Twenty-Four-Month Results of Intravitreal Bevacizumab in Macular Edema Secondary to Branch Retinal Vein Occlusion

被引:9
|
作者
Tsagkataki, M. [1 ]
Papathomas, T. [1 ]
Lythgoe, D. [2 ]
Kamal, A. [1 ]
机构
[1] Aintree Univ Hosp NHS Fdn Trust, Dept Ophthalmol, Liverpool L9 7AL, Merseyside, England
[2] Liverpool CR UK Ctr, Liverpool, Merseyside, England
关键词
Avastin; macular oedema; retinal ischaemia; visual acuity; vein occlusion; THERAPY; INJECTION; AVASTIN(R); CYTOKINES;
D O I
10.3109/08820538.2013.874488
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: The aim of this study is to evaluate the long-term efficacy of intravitreal bevacizumab (IVB) in macular edema (ME) due to branch retinal vein occlusion (BRVO) in a real clinical practice setting at a tertiary referral center. Methods: A retrospective analysis of a final total number of 35 eyes of 35 patients with a 24-month follow-up was performed. Results: At 24 months, mean best-corrected visual acuity improved by 0.09 LogMAR units from baseline (95% CI: -0.03-0.24, p=0.0674). The mean CFT decreased by 75 microns (95% CI: 27-123, p=0.0026). The median number of injections was 6 (IQR: 3-9). Macular edema showed complete resolution in 12 eyes (34.3%), responded partially in six eyes (17%), recurred in eight eyes (23%), and remained persistent in nine eyes (25.7%, three eyes at six months, one eye at 12 months, three eyes at 18 months and two eyes at 24 months). Conclusion: Our study shows that treatment with IVB in patients with ME due to BRVO during a period of 24 months provided complete resolution of the ME in more than one-third of patients. In one-third of the cases, ME resolved partially or recurred and in less than one-third of patients ME remained persistent. Visual acuity increased significantly in 23% of patients and remained stable in the majority of patients. However, a median number of six injections was necessary to maintain a lasting beneficial effect. Further long-term prospective studies are required comparing intravitreal bevacizumab with other treatment modalities.
引用
收藏
页码:352 / 359
页数:8
相关论文
共 50 条
  • [21] One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion
    Jaissle, Gesine B.
    Leitritz, Martin
    Gelisken, Faik
    Ziemssen, Focke
    Bartz-Schmidt, Karl Ulrich
    Szurman, Peter
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2009, 247 (01) : 27 - 33
  • [22] One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion
    Gesine B. Jaissle
    Martin Leitritz
    Faik Gelisken
    Focke Ziemssen
    Karl Ulrich Bartz-Schmidt
    Peter Szurman
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247
  • [23] Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion
    Donati, Simone
    Barosi, Paolo
    Bianchi, Marco
    Al Oum, Muna
    Azzolini, Claudio
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2012, 22 (04) : 607 - 614
  • [24] Intravitreal bevacizumab associated with grid laser photocoagulation in macular edema secondary to branch retinal vein occlusion
    Salinas-Alaman, Angel
    Zarranz-Ventura, Javier
    Caire Gonzalez-Jauregui, Jose M.
    Sadaba-Echarri, Luis M.
    Barrio-Barrio, Jesus
    Garcia-Layana, Alfredo
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2011, 21 (04) : 434 - 439
  • [25] Results of intravitreal triamcinolone acetonide in patients with macular edema secondary to branch retinal vein occlusion
    Mehmet Demir
    Ersin Oba
    Dilek Guven
    Zeynep Acar
    Sonmez Cinar
    International Journal of Clinical Pharmacy, 2014, 36 : 438 - 442
  • [26] Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
    Mesa Gutierrez, Juan Carlos
    Arias Barquet, Luis
    Caminal Mitjana, Josep Maria
    Prades Almolda, Sergi
    Planas Domenech, N-Ria
    Pujol Goita, Octavi
    Rubio Caso, Marc
    Arruga Ginebreda, Jorge
    CLINICAL OPHTHALMOLOGY, 2008, 2 (04): : 787 - 791
  • [27] Comparison of Natural Course, Intravitreal Triamcinolone, and Intravitreal Bevacizumab for Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion
    Kwon, Soon Il
    Kim, Young Wook
    Bang, Ye Won
    Lee, Joo Yeon
    Park, In Won
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2013, 29 (01) : 5 - 9
  • [28] Results of intravitreal triamcinolone acetonide in patients with macular edema secondary to branch retinal vein occlusion
    Demir, Mehmet
    Oba, Ersin
    Guven, Dilek
    Acar, Zeynep
    Cinar, Sonmez
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2014, 36 (02) : 438 - 442
  • [29] Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion
    Kreutzer, T. C.
    Alge, C. S.
    Wolf, A. H.
    Kook, D.
    Burger, J.
    Strauss, R.
    Kunze, C.
    Haritoglou, C.
    Kampik, A.
    Priglinger, S.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2008, 92 (03) : 351 - 355
  • [30] Recurrence of macular edema associated with branch retinal vein occlusion after intravitreal bevacizumab
    Hanada, Narihisa
    Iijima, Hiroyuki
    Sakurada, Yoichi
    Imasawa, Mitsuhiro
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2012, 56 (02) : 165 - 174